You are here: Industry Insights > AZD1222

News List

Emergent expands Covid-19 vaccine manufacturing deal with AstraZeneca pharmaceutical-technology
July 29, 2020
Emergent BioSolutions has entered into an agreement valued at approximately $174m for large-scale commercial production of drug substance for AstraZeneca Covid-19 vaccine candidate, AZD1222.
COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial worldpharmanews
July 21, 2020
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.
Catalent, AstraZeneca Ink Mfg. Pact for COVID-19 Vax contractpharma
June 16, 2020
Catalent preparing for large-scale commercial supply of the University of Oxford’s COVID-19 vaccine candidate AZD1222 starting August 2020.
Oxford Biomedica Signs Collaboration Agreement with VMIC contractpharma
June 15, 2020
Will work collaboratively to enable the manufacture of viral vector-based vaccines.
AstraZeneca and Emergent Enter COVID-19 Vax Agreement contractpharma
June 15, 2020
Emergent to provide development and manufacturing services and secure large-scale manufacturing capacity through 2020 for AstraZeneca’s COVID-19 vax candidate.
Serum Institute to invest $100 million on potential COVID-19 vaccine expresspharma
June 10, 2020
It has partnered with AstraZeneca, a British company, to ensure equitable supply of the AZD1222 vaccine doses to India as well as low-and-middle-income countries.
AstraZeneca Takes Next Steps Towards Broad Access to Oxford’s COVID-19 Vaccine contractpharma
June 09, 2020
Agreements with CEPI and Gavi and the Serum Institute of India will bring vaccine to low and middle-income countries and beyond.
Oxford Biomedica partners VMIC for vaccine manufacturing pharmaceutical-technology
June 09, 2020
UK-based gene and cell therapy group Oxford Biomedica has partnered with non-profit Vaccines Manufacturing and Innovation Centre (VMIC) for the manufacturing of viral vector-based vaccines.
CDMO delivers 4000 doses of COVID-19 vaccine candidate for Phase II/III trial europeanpharmaceuticalreview
June 01, 2020
Advent announced it has manufactured and delivered the first 4000 doses of the AZD1222 vaccine candidate for the University of Oxford clinical trial.
AstraZeneca Gets $1B from U.S. to Deliver COVID-19 Vax by Fall contractpharma
May 26, 2020
Aims to make potential COVID-19 vaccine AZD1222 widely accessible with first deliveries in September 2020.

Previous page 1 2 3 4 Next page